DOCSLIB.ORG

Pfizer Celebrates UK Viagra Switch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pfizer Celebrates UK Viagra Switch Time to J&J targets Deals grab explorethe Devine right headlines Silk Road to win in 2017 page 10 page 18 page 20 Contents Pfizer celebrates 15 December 2017 Issue Number 494 COMPANY NEWS UK Viagraswitch Nestlé makes Atrium move 3 en in the UK will soon have OTCac- UK pharmacies “in the spring of 2018”. Alliance snaps up 4 Mcess to Pfizer’s blockbuster erectile- “Inthe interim,”Pfizer added, “the company Vamousse range dysfunction treatment Viagra after an appli- will be implementing an extensive trainingand HRAPharmaeagerly 5 cation to switch the sildenafil-based product education programme with pharmacies.” seeking acquisitions wasgiven the green light. Viagra Connect will be available from a Damier growswith Remark5 Following aconsultation –launched earlier pharmacist without aprescription for men aged this year (OTC bulletin,7April 2017, page 18 years or older suffering from erectile dys- Venture Life to grow 6 9) –the UK’s Medicines andHealthcare prod- function. The maximum dose is one tablet a global OTCoffering ucts Regulatory Agency(MHRA) approvedthe day,with apack size of up to eight tablets. Phoenix increases7reclassification of sildenafil50mg film-coated Theapprovalwill be areal boon to Pfizer’s presenceinSerbia tablets from prescription-only medicine (POM) Consumer Healthcareoperation, which is cur- ZurRosesnaps up another rival7 to pharmacy(P) status. rently under“strategicreview”. Pfizer will make The MHRA–which pointedout that other adecision on whetherto sell theunit next year GENERAL NEWS medicines containing sildenafil would still be (OTC bulletin,20October 2017, page 1). GSK suveysCanadians 8 available on prescription –confirmed to OTC Noting that it had approvedthe switch “fol- bulletin that generic 50mgformulations would lowing areassuring assessment of the safety FDAeases app focus 11 remain prescription-only unless and until they of Viagra Connect and advice from the UK’s Optimisation keytogrowth 11 successfully underwent asimilar switch procedure. Commission on Human Medicines”, the MHRA France investigates 14 Pfizer vere aled that it wasalready “work- pointed out that the product would only be sold OTCsale monopoly ing on plans” to introduce OTCsildenafil – after adiscussion with apharmacist. under the brand name Viagra Connect –in Continued on page 8 MARKETING NEWS DocMorris launches 15 chronic illness app WBAbreaks intoChina GSK keeps hands clean 15 algreens BootsAlliance (WBA) is pois- Headquartered in Shanghai, GuoDaoperates ASA clears Nurofen 16 Wed to break into China’sretail phar- more than 3,500 retail pharmacies in 70 cities of misleading TV ad macymarket by grabing aminority stake across China and is the country’snumber one ACCC goes forVoltaren 16 in the country’sGuoDa drugstore chain. pharmacychain by sales. Under the terms of the deal, WBAwill pay Describing GuoDa as “China’sleading phar- REGULARS Sinopharm Accord CNY2.77 billion (C355 mil- macy chain”, WBApointed outthat the drug- Events –Our regular listing 17 lion) to take a40% stakeinits subsidiary Sino- store operator had been seeking outside invest- People –Bayer announces 24 pharm HoldingGuoDaDrugstores. Thetrans- ment to support its strategy for “expansion newUKOTC head action is subject to regulatory approvaland across the country”. GuoDa waslooking to other closing conditions. Continued on page 5 Connect with us on: Twitter LinkedIn OTC-bulletin.com Youfocus on GREA V T consumer healthcare ALUE Indiv idu subscrip al So do we ... tio are onl ns y Letus bring you thenews £995 that matters to your industry Don’twaste time sifting through pharma noise. OTC bulletin delivers all thewellness and self-care informationyou needto makebetter decisions faster. CHOICE OF FORMATS OTC bulletin newslettersare available: ■ EITHER as the digital OTC bulletin-i foronline access by desktop and laptop computersAND Apple and Android tablets and smartphones ■ OR in traditional hard-copyprint format PRINT DESKTOP APPLE ANDROID INDIVIDUAL SUBSCRIPTIONS An annual subscription comprises: ■ 20 OTC bulletin newsletters ■ AND at least 45 weekly news@OTCbulletin electronic newsflashes containing the week’s topnewsstories, deliveredbyemail MULTIPLE&CORPORATE SUBSCRIPTIONS Discounts are available formulti-user subscriptions for colleagues at the same location. Researchedand writtenby Corporatesubscriptions provide location-, country- or consumer healthcarespecialists company-wide access to OTC bulletin. from an OTC industry perspective Take out your own subscriptionTODAY at www.OTC-bulletin.com or for Corporatesubscriptions contact: [email protected] Bulletin Publishing Group, OTCPublications Ltd, 4PoplarRoad,Dorridge,SolihullB93 8DB, UK. (Tel: +44 (0)1564 777550; Fax: +44 (0)1564 777524).Registered in England No. 2765878. VATGB608 0432 69 COMPANY NEWS OTC Mergers &Acquisitions Nestlé makes Atrium move estlé has signalled its intention to become Science division, which offers “science-based Naforce in consumer healthcare by acquir- nutritional solutions” direct to consumers and ing Canadian supplements specialist Atrium through healthcare professionals. Innovationsfor US$2.3billion (C1.95 billion) Commenting on the deal, GregBehar,Nestlé fromagroup of investors led by PermiraFunds. Health Science’schief executive officer,said Subjecttoregulatoryapproval,the transaction is Atrium’sbrands “naturally complemented” expected to close in the first quarter of 2018. Health Science’sConsumer Care portfolio. Describing Atrium as a“global leader in “Atrium’sportfolio will extend our product nutritional health products”, Nestlé said the range with value-added solutions such as pro- deal supported its “pursuit of growth oppor- biotics, plant-based protein nutrition, meal re- The Wobenzym Njoint-health supplement tunities in consumer healthcare, complement- placementsand an extensivemultivitaminline,” bulletin,6October 2017, page 5). ing the company’sfocus on its high-growth Behar noted. “Atrium’sestablished brands are in Prior to itstakeoverbyNestlé, Atrium in late food and beverage categories”. attractivecategories andhavethe potential for November struck astrategic partnership with Quebec-based Atrium wasexpected to gen- continued stronggrowth as part of Nestlé through Chinese cross-border e-commerce platform Net- erate turnoverof“almost US$700 million” in category, channel andgeographic expansion.” Ease Kaola to gain better access to China’s grow- 2017,Nestlé noted,from sales in morethan50 Thedeal alsogaveNestlé afoothold in the ingmiddle class consumer base. countries across North America, Europe and Asia. “fast growing” segment for “organic andnatu- Atrium’sbest-selling line, the Garden of ral supplements”, Behar said. Deal with NetEase Life organic supplements range, wasthe “num- Peter Luther,Atrium’spresident and chief The Canadian firm said striking adeal with ber-one brand in the natural supplements indus- executive officer, said the firm was“looking for- one of China’s“fastest growing e-commerce try in the US”, Nestlé claimed, while the Pure ward to continued growth as part of Nestlé”. companies” would enable Atrium to expand its Encapsulations hypoallergenic supplements line “Nestlé will provideAtrium with the resources limited presence in the East Asian country. wasthe “number-one recommended brand in to accelerate the growth of our brands,”Luther Atrium entered theChinese market in 2016, the US practitioner market”. added, “and to reach more consumers globally.” by establishing wholly-owned subsidiaries in Both brands are also available in China, as Nestlé’sacquisition of Atrium comes six Shanghai and Hong Kong. is the Wobenzym supplement line, which is months after the Swiss food and drinks giant Expanding on the rationale behind the agree- claimed to “promote joint health and help re- committed to growing its presence in the global ment, LuthersaidNetEase Kaola’sunderstand- lieve everyday aches and pains”. consumer healthcare market (OTC bulletin,21 ingof“shopperinsight” and “purchasing behav- Atrium’sEuropean portfolioincludes theAOV July 2017, page 7). iour” would help Atrium to tap into the “huge alternative medicine line, Orthica probiotics Commenting on this strategy in October, potential” of the Chinese market. and Minami omega-3 range, as well as Pure Nestlé’schief executive officer,Mark Schneider, Atrium’sbrands –such as Wobenzym and Encapsulations and Wobenzym. said the companywas interested in “anything Garden of Life –offered “unique benefits” for Nestlé noted that upon closing Atrium’s thatisclose to our core skillsetaround nutri- those Chinese consumers “looking for more management team would remain in place and tion and skin, and anythingthatgives us astrong- natural, clean and provensupplements from the it would incorporate thebusiness into its Health er presence in the drugstore channel” (OTC international market”, Luther claimed. OTC Editor: Matt Stewart Assistant Editor: RachaelWalker Advertising Controller: Debi Robinson Deputy Editor: Tom Gallen Production Editor: Jenna Meredith Director of Subscriptions: Val Davis AssociateEditor: David Ridley Editor-in-Chief: Aidan Fry Group Sales Manager: Rob Coulson Contributing Editor: David Wallace Managing Director: Phil Jarvis Awards Manager: Natalie Cornwell 15 December 2017 |Number 494 Editorial enquiries: OTC bulletin, Te rms &Conditions: While due carehas been taken to ensurethe accuracy of 4 Poplar Road, Dorridge,Solihull, These can be viewedinfull at www.OTC-bulletin.com. information contained in this publication, the publisher West Midlands B93 8DB, UK. No partofthis publication
Load more

Recommended publications
  • Correlation of Physicochemical Properties of Model Drugs and Aerosol Deposition
    CORRELATION OF PHYSICOCHEMICAL PROPERTIES OF MODEL DRUGS AND AEROSOL DEPOSITION w ANA CATARINA MATOS DE OLIVEIRA A thesis submitted for the degree of Doctor of Philosophy Department of Pharmaceutics The School of Pharmacy, University of London 29-39 Brunswick Square London WC IN 1 AX, UK MARCH 2009 ProQuest Number: 10104755 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104755 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Plagiarism Statement This thesis describes research conducted in the School of Pharmacy, University of London between 2004 and 2008 under the supervision of Prof. Graham Buckton and Dr. Simon Gaisford. I certify that the research described is original and that any parts of the work that have been conducted by collaboration are clearly indicated. I also certify that I have written all the text herein and have clearly indicated by suitable citation any part of this dissertation that has already appeared in publication. Signature Date Abstract Dry powder inhalers (DPIs) are recognized devices for the administration of medicines to the lungs.
    [Show full text]
  • Supply and Demand for Medicines Published in Scotland by the Scottish Parliamentary Corporate Body
    Published 30 June 2020 SP Paper 774 6th Report, 2020 (Session 5) Health and Sport Committee Comataidh Slàinte is Spòrs Supply and demand for medicines Published in Scotland by the Scottish Parliamentary Corporate Body. All documents are available on the Scottish For information on the Scottish Parliament contact Parliament website at: Public Information on: http://www.parliament.scot/abouttheparliament/ Telephone: 0131 348 5000 91279.aspx Textphone: 0800 092 7100 Email: [email protected] © Parliamentary copyright. Scottish Parliament Corporate Body The Scottish Parliament's copyright policy can be found on the website — www.parliament.scot Health and Sport Committee Supply and demand for medicines, 6th Report, 2020 (Session 5) Contents Executive Summary _____________________________________________________1 Introduction ____________________________________________________________4 Engagement___________________________________________________________4 Structure of the report ___________________________________________________5 Background ___________________________________________________________6 Research and development _______________________________________________8 Real-world experience and clinical trials _____________________________________8 Personalised medicine___________________________________________________9 Waste _____________________________________________________________10 Manufacturing technology _____________________________________________10 Preparedness for personalised medicine in the healthcare system ______________10
    [Show full text]
  • Why Humidify? for Pharmaceuticals
    Why humidify? For pharmaceuticals... Humidification and Evaporative Cooling Trusted Technology Nortec humidifiers by Condair are waste and enhance productivity. Some evaporative cooling systems to help used in pharmaceutical processing and of the world’s leading pharmaceutical them meet their production objectives. research facilities around the world manufacturers put their trust to maintain product quality, reduce in Condiar humidification and AstraZeneca, UK Sanofi Aventis Vostok, Russia GlaxoSmithKline, UK TEVA, Russia Elanco, Canada Abbott Laboratories, Ireland Pfizer, UK Roche Penzeberg, Germany Apotex, Canada Boston Scientific, Ireland Eli Lilly, UK Bristol-Myers Squibb, Germany Astellas Pharma Europe, Netherlands Roche Kaiseraugust, Switzerland Promega Corporation, USA TEVA Pharmachemie, Netherlands GE Healthcare, Austria Novo Nordisk Pharmaceuticals Co Ltd, China SPL, USA Laboratorios Bayer, Spain DSM, Netherlands Nobel and World Medicine, Turkey Xian Janssen Pharmaceuticals Ltd, China Pfizer, USA Laboratorios Beechmann, Spain Teva and Taro, Israel Sanofi (Beijing) Pharmaceuticals Co Ltd, China Incyte Pharmaceutical, USA Picking Farma, Spain Neopharma, United Arabic Emirates Beijing Novartis Pharmaceuticals Co Ltd, China Kremers Urban Pharmaceuticals, USA Productos Roche S.A., Spain Spimaco, Saudi Arabia Taizhou Astra Zeneca Pharmaceuticals Co Ltd, China MEDCO/Express Scripts, USA QG Medical Devices, Qatar Purdue Heine Pharmacy, USA Cipla, India St Francis Hospital Pharmacy, USA Lupin, India Beckman Coulter, USA Zydus Cadila,
    [Show full text]
  • The World's Leading Global M&A Partnership Since 1973
    IMAP The world’s leading global M&A partnership since 1973 www.imap.com IMAP DEALBOOK 2017-2018 IMAP DEALBOOK 2017-2018 Contents FOREWORD 6 ABOUT IMAP 8 12 18 28 38 Automotive Building Business Consumer Products Services & Retail & Services 76 86 98 106 Healthcare Industrials Materials, Real Estate Chemicals & Mining 48 52 58 66 Education Energy Financial Food & & Training & Utilities Services Beverage 112 128 Technology Transport & Logistics Jurgis V Oniunas IMAP Chairman “We deliver, transaction after transaction, intimate industry-related knowledge, excellence in execution and the very best tailored M&A financial advice.” 7 Foreword There is little room for doubt that we are close deals across sectors and on a global living in unsteady times. World trade is under scale. Thanks to ongoing commitment, cross- pressure amid rising protectionism and the border collaboration and distinguished sector geopolitical system is going through tectonic expertise, IMAP continues to hold its position as shifts. Technological disruption, demographic one of the world’s leading global M&A advisories imbalances and immigration are also having an for the mid-market. We know our clients come impact. Moreover, there is a rising realization back to us because we deliver, transaction after that the business cycle may soon reverse transaction, intimate industry-related knowledge, into recession. And yet, at IMAP we remain excellence in execution and the very best positive about the promise of opportunity from tailored M&A financial advice. major advances in science, technology and medicine, changing the way we think about About 35% of IMAP deals are cross-border, many issues, from logistics to aging.
    [Show full text]
  • The Academy of Medical Sciences 2008 FORUM Annual Lecture the UK Pharmaceutical Industry: What Does the Future Hold?
    The Academy of Medical Sciences 2008 FORUM Annual Lecture The UK pharmaceutical industry: what does the future hold? Academy of Medical Sciences Andrew Witty, CEO, GlaxoSmithKline 10 Carlton House Terrace London, SW1Y 5AH Tel: +44(0)20 7969 5288 Fax: +44(0)20 7969 5298 Email: [email protected] Web: www.acmedsci.ac.uk The Academy of Medical Sciences The Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are converted into healthcare benefits for society. Our Fellows are the UK’s leading medical scientists from hospitals and general practice, academia, industry and the public service. The Academy seeks to play a pivotal role in determining the future of medical science in the UK, and the benefits that society will enjoy in years to come. We champion the UK’s strengths in medical science, promote careers and capacity building, encourage the implementation of new ideas and solutions – often through novel partnerships – and help to remove barriers to progress. The Academy’s FORUM with industry The Academy’s FORUM is an active network of scientists from industry and academia, with representation spanning the pharmaceutical, biotechnology and other health product sectors, as well trade organisations, Research Councils and other major charitable research funders. Through promoting interaction among these groups, the FORUM aims to take forward national discussions on scientific opportunities, technology trends and the associated strategic choices for healthcare and other life-science sectors. The FORUM builds upon what is already distinctive about the Academy: its impartiality and independence, its focus on research excellence across the spectrum of clinical and basic sciences and its commitment to interdisciplinary working.
    [Show full text]
  • This Article Was Originally Published in Issue 6.3 Of
    Year 6, Issue 3 CEE APRIL 2019 Legal Matters 2019 Corporate Counsel Handbook ELİG GÜRKAYNAK Attorneys at Law INTEGRITY EFFICIENCY COMMITMENT ELIG Gürkaynak Attorneys-at-Law is an eminent, independent Turkish law firm founded in 2005. The firm is based in Istanbul. Widely recognized as having the leading competition law practice in Turkey, our team consists of 45 dedicated competition law specialists led by Gönenç Gürkaynak, the firm’s partner with more than 20 years competition law experience, along with four partners and two counsel. Our competition law team at ELIG Gürkaynak Attorneys-at-Law has a unique understanding and significant experience in a range of industries including pharmaceuticals, transportation & airlines, food & agricultural products, manufacturing, telecommunications, media & technology, healthcare & medical devices, energy, tobacco, construction and defense. In addition to our unparalleled experience in merger control issues, our team has vast experience in defending companies before the Turkish Competition Board in all phases of antitrust investigations, abuse of dominant position cases, leniency handlings, and before the courts on issues of private enforcement of competition law, along with appeals of the administrative decisions of the Turkish Competition Authority. ELIG (Gürkaynak) Attorneys-at-Law is still the first name … when it comes to We take pride in being able to assist our clients in all fields of law. “competition advice in Turkey. The team is led by Gönenç Gürkaynak and consists Our areas of expertise particularly include: competition law of 45 specialists… and - uniquely in Turkey - a full-time, in-house competition • corporate law • M&A • contracts law • white collar irregularities and economist.
    [Show full text]
  • MSN2021 004 Voriconazole
    Medicine Supply Notification MSN/2021/004 Voriconazole 200mg powder for solution for infusion Tier 2 - medium impact* Date of issue: 14 January 2021 Summary • Pfizer and Bowmed are currently out of stock of voriconazole 200mg vials. • Bowmed expects resupply w/c 18th January. • Fresenius Kabi remains in stock but cannot support the demands of their non-contracted regions during this period. • Pfizer have sourced an alternative product, packaged for the Saudi Arabian market (English labelled) which can support from w/c 18th January until UK licensed stock is resupplied during the course of February. This stock is unlicensed in the UK. • Specialist importers have indicated that other unlicensed imports can be sourced, lead times vary. Actions Required Trust/Health Board pharmacy procurement teams in Bowmed and Pfizer contracted regions should work with clinical leads and the local Medication Safety Officer (MSO) to ensure the following actions are undertaken where relevant: • review local stock holding of voriconazole 200mg vials against anticipated demand and identify if the organisation will need additional supply to bridge the gap until their supplier is back in stock; • work with their Regional Pharmacy Procurement Specialist (RPPS) to share stock locally, to ensure continuity of care for patients; • consider switching patients to oral voriconazole or using an alternative antifungal agent where clinically appropriate; • if therapeutic switching is not possible/appropriate place orders for imports; and • if Trusts are likely to have multiple unlicensed products in use within the organisation at the same time consideration is given and mitigations put in place to minimise the risk of product confusion and dosing errors.
    [Show full text]
  • Cphi Annual Industry Report 2019
    New modalities, new methods and new thinking to solve old problems Industry Expert Panel Submissions CPhI Annual Industry Report 2019 Released at CPhI Worldwide, 5 - 7 November, 2019 Frankfurt, Germany www.cphi.com The CPhI Annual Report is a comprehensive and critically important publication that analyses key trends and innovations forecast by our panel of world class experts. Running as a series of opinions and articles, the CPhI experts call upon their considerable commercial and technical acumen to prophesize the future direction, technologies, opportunities and threats in pharma. It’s an essential read for executives who wish to get a head start today on the shape of tomorrow’s industry. Contents CPhI’s Pharma Industry Rankings: Evaluation of current Pharma ...................................................................................... 3 Part 1. Innovation, AI and Regulation Building Quality into Pharma Manufacturing, from Molecule to Medicine: Pharma 4.0 .........................................12 BIKASH CHATTERJEE, PRESIDENT AND CHIEF SCIENCE OFFICER, PHARMATECH ASSOCIATES Chaos to Continual Improvement: Path to Harmonization ................................................................................................20 AJAZ HUSSEIN PHD, THE NATIONAL INSTITUTE FOR PHARMACEUTICAL TECHNOLOGY & EDUCATION, INC., USA Pharmaceutical Quality: Concepts, Misconceptions, Realities And Remedies ............................................................31 GIRISH MALHOTRA PRESIDENT AT EPCOT INTERNATIONAL Part 2. Biologics (Capacity
    [Show full text]
  • Drug Discovery: a History
    ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK Copyright u 2005 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [email protected], or faxed to (+44) 1243
    [Show full text]
  • Baltic Top 50 2014
    panoramaTHE COFACE ECONOMIC PUBLICATIONS July 2014 BALTIC TOP 50 2014 CONTENTS Coface is publishing its second edition of the Baltic Top 50. The companies are ranked based on their turnover in 2013. Figures for 2013 show the continuing recovery of the Baltic states. The / 02 Coface Baltic Top 50: Ranking and methodology total turnover of the top players in the North increased by 2.2% to EUR 36.2 billion. Whereas net profits fell from 2011 to 2012, companies have now reported a sharp rise of 54.6%. / 03 Country analysis and country ranking Top 3 largest companies in the Baltics / 07 Sector analysis and It is hard to beat the three top companies in the Baltics. With a sector ranking turnover of EUR 6.1 billion, the oil and gas giant Orlen Lietuva is again number 1, although it has some problems to contend with. Both Coface contacts second-placed Vilniaus Prekyba (EUR 3 billion) and the third-placed / 09 Maxima Grupe (EUR 2.5 billion) increased their turnover by around 6% and net profits by around 20%. Country Analysis Lithuania, already home to a majority of the top companies in 2012 (29), was able to further strengthen its leading position (+2). Unsurprisingly, the country also contributed the largest share in turnover (71.5% or almost EUR 26 billion, +2.7%). Although the Latvian economy still exhibits the highest GDP growth in 2013, its top players were not able to continue their double-digit growth rates from the previous year. In total, turnover by the eleven (-1 company) Latvian top companies decreased by 2.9%.
    [Show full text]
  • 2018-Annual-Report.Pdf
    Contents Welcome from the Chair ................................................................................................................................................................. 3 Treasurer’s Report ........................................................................................................................................................................... 5 Membership Report ......................................................................................................................................................................... 6 Partnership Report ........................................................................................................................................................................... 7 Commercial Report .......................................................................................................................................................................... 8 Careers & Academic Liaision Committee (CALC) ...................................................................................................................... 9 External Affairs ............................................................................................................................................................................... 11 Communication & Publications Report ....................................................................................................................................... 12 PSI/EFSPI Regulatory Report .....................................................................................................................................................
    [Show full text]
  • 2015 Annual Review
    2015 ANNUAL REVIEW PFIZER 2015 ANNUAL REVIEW www.pfizer.com/annual Homepage 1 2015 ANNUAL REVIEW 2015: A TRANSFORMATIONAL YEAR 2015 was a transformational year for Pfizer in our journey to achieve our stated mission: to be the premier, innovative biopharmaceutical company in our industry by the end of this decade. Ian C. Read Chairman & CEO TO OUR STAKEHOLDERS: Innovation, commitment, quality and integrity are the hallmarks of our business, from the development of innovative new products to the delivery of new therapies to patients. Thanks to the more than 97,000 Pfizer colleagues around the world we met our yearly commitments and continued to build the company’s capabilities toward our goal to become the world’s premier, innovative biopharmaceutical company by the end of this decade. PFIZER 2015 ANNUAL REVIEW www.pfizer.com/annual CEO Letter > Letter to Stakeholders 2 2015 ANNUAL REVIEW Notably, in 2015, Pfizer achieved its first year of operational revenue growth since 2009. This occurred largely due to the strong performance of new product launches and OUR PURPOSE despite facing several difficult challenges including overcoming another $3.2 billion in losses of exclusivity, the slowdown in several global markets, and the continued pressure INNOVATE TO BRING THERAPIES TO PATIENTS on access and pricing for our medicines. Our return to operational revenue growth is a THAT SIGNIFICANTLY IMPROVE THEIR LIVES sign that our efforts to speed up innovation are taking hold. In 2015, we also took transformative steps to position Pfizer for the future with the acquisition of Hospira, Inc. and our pending combination with Allergan.
    [Show full text]